Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

► Without certainty on the functionality of an drug target clinical studies should not be started. ► We need to try to predict Drug-Registration in the earliest clinical studies. ► The most important biomarker is the patient selection biomarker. ► Get the pharmacology right before moving on. ► Choices on drug combinations should be based on biological rationales.